View Older Stories

Jan 30, 2026 06:47AM Protagonist Therapeutics (PTGX) PT Raised to $117 at H.C. Wainwright

Jan 27, 2026 06:52AM JPMorgan on Protagonist Therapeutics (PTGX): 'The Kids Are Almost Out of the House'

Jan 5, 2026 09:38AM Protagonist Therapeutics (PTGX) PT Raised at Truist Ahead of 'Pivotal Year'

Jan 5, 2026 07:03AM Takeda and Protagonist submit drug application for polycythemia vera treatment

Dec 12, 2025 04:54AM Protagonist's (PTGX) Economics Can Change After Takeda Opt-out - Citizens

Dec 8, 2025 02:54AM Protagonist and Takeda report 52-week rusfertide data in polycythemia vera

Nov 20, 2025 04:00AM Jefferies Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Nov 7, 2025 05:04AM Protagonist Therapeutics (PTGX) PT Raised to $91 at Clear Street

Nov 6, 2025 06:42PM Protagonist Therapeutics (PTGX) Tops Q3 EPS by 1c

Nov 6, 2025 04:05PM Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 28, 2025 09:26AM Protagonist Therapeutics (PTGX) PT Raised to $88 at Truist Securities

Oct 13, 2025 02:04PM Protagonist Therapeutics (PTGX) Said to Be Mentioned Cautiously Regarding M&A

Oct 13, 2025 05:04AM Protagonist Therapeutics (PTGX) PT Raised to $112 at BMO Capital

Oct 10, 2025 01:06PM Protagonist Therapeutics (PTGX) January 95 calls active, share price up 32%

Oct 10, 2025 11:27AM Protagonist Therapeutics stock surges after J&J acquisition talks report

Oct 10, 2025 11:16AM Protagonist Therapeutics (PTGX) halted on volatility

Oct 10, 2025 11:14AM Johnson & Johnson (JNJ) in talks to buy Protagonist Therapeutics (PTGX) - WSJ

Oct 8, 2025 09:08AM BMO Capital on Protagonist Therapeutics (PTGX): 'UEG Icotrokinra Full Data Remains Compelling'

Oct 7, 2025 11:00PM Jefferies says this stock offers favorable setup with further upside potential

Oct 7, 2025 02:50PM Protagonist Therapeutics (PTGX) PT Raised to $74 at Clear Street

Sep 17, 2025 04:35AM Barclays Starts Protagonist Therapeutics (PTGX) at Overweight

Sep 12, 2025 06:02AM Leerink Partners Starts Protagonist Therapeutics (PTGX) at Outperform

Aug 7, 2025 04:18AM Protagonist Therapeutics (PTGX) PT Raised to $69 at Citizens JMP

Aug 6, 2025 06:25PM Protagonist Therapeutics (PTGX) Tops Q2 EPS by 3c

Aug 6, 2025 04:05PM Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 1, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Jun 17, 2025 05:19AM Citi Starts Protagonist Therapeutics (PTGX) at Buy

Jun 3, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Jun 3, 2025 05:47AM Protagonist Therapeutics (PTGX) PT Lowered to $62 at Clear Street

Jun 3, 2025 05:16AM BTIG Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Jun 2, 2025 10:29AM JPMorgan Reiterates Overweight Rating on Protagonist Therapeutics (PTGX)

May 6, 2025 04:05PM Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 11, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Apr 11, 2025 05:15AM BTIG Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Mar 11, 2025 09:02AM Protagonist Therapeutics (PTGX) PT Raised to $72 at BMO Capital Post ANTHEM/ICONIC Data

Mar 10, 2025 02:16PM Jefferies Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Mar 10, 2025 09:34AM Protagonist Therapeutics (PTGX) PT Raised to $76 at Truist Securities

Mar 10, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Mar 10, 2025 05:12AM BTIG Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Mar 10, 2025 04:28AM Citizens JMP Reiterates Market Outperform Rating on Protagonist Therapeutics (PTGX)

Mar 4, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Mar 3, 2025 02:34PM Protagonist Therapeutics (PTGX) PT Raised to $73 at BTIG

Mar 3, 2025 01:28PM Truist Securities Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Mar 3, 2025 01:21PM TD Cowen Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Mar 3, 2025 11:52AM Protagonist Therapeutics (PTGX) PT Raised to $57 at JPMorgan

Mar 3, 2025 06:46AM Protagonist Therapeutics (PTGX) and Takeda (TAK) Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Feb 28, 2025 08:44AM JPMorgan Reiterates Overweight Rating on Protagonist Therapeutics (PTGX)

Feb 24, 2025 07:10AM Protagonist Therapeutics (PTGX) PT Raised to $54 at H.C. Wainwright

Feb 21, 2025 07:00AM Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 19, 2025 04:41AM Citizens JMP Reiterates Market Outperform Rating on Protagonist Therapeutics (PTGX)

View Older Stories